Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 5, 2004, Pages 328-336

  Cutler, Corey ^a   Kim, Haesook T ^a   Hochberg, Ephraim ^a   Ho, Vincent ^a   Alyea, Edwin ^a   Lee, Stephanie J ^a   Fisher, David C ^a   Miklos, David ^a   Levin, Jesse ^a   Sonis, Stephen ^b   Soiffer, Robert J ^a   Antin, Joseph H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Graft versus host disease; Methotrexate; Peripheral blood stem cell transplantation; Sirolimus

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DACLIZUMAB; DEFIBROTIDE; GEMTUZUMAB OZOGAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BK VIRUS; BLOOD DONOR; CAUSE OF DEATH; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMOLYSIS; HLA MATCHING; HOSPITAL DISCHARGE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY DYSFUNCTION; LIVER VENOOCCLUSIVE DISEASE; LUNG HEMORRHAGE; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; MYCOSIS; NEUTROPHIL; PERIOPERATIVE PERIOD; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RELAPSE; SURVIVAL RATE; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIREMIA; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SIROLIMUS; SURVIVAL ANALYSIS; TACROLIMUS; TREATMENT OUTCOME;

EID: 11144354152     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2003.12.305     Document Type: Article

References (63)

1. Storb R. Deeg H.J. Pepe M. et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial Blood 73 1989 1729-1734
2. Champlin R.E. Schmitz N. Horowitz M.M. et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation Blood 95 2000 3702-3709
3. Ghosh P. Buchholz M.A. Yano S. Taub D. Longo D.L. Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway Blood 99 2002 4517-4524
4. Kirken R.A. Wang Y.L. Molecular actions of sirolimus: sirolimus and mTor Transplant Proc 35 3 suppl 2003 S227-S230
5. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression Clin Biochem 31 1998 335-340
6. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action Transplant Proc 353 suppl 2003 S7-S14
7. Hackstein H. Taner T. Zahorchak A.F. et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo Blood 101 2003 4457-4463
8. Hackstein H. Taner T. Logar A.J. Thomson A.W. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells Blood 100 2002 1084-1087
9. Monti P. Mercalli A. Leone B.E. et al. Rapamycin impairs antigen uptake of human dendritic cells Transplantation 75 2003 137-145
10. Woltman A.M. de Fijter J.W. Kamerling S.W. et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages Blood 98 2001 174-180
11. Woltman A.M. van der Kooij S.W. Coffer P.J. et al. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression Blood 101 2003 1439-1445
12. Johnson R.W. Sirolimus (Rapamune) in renal transplantation Curr Opin Nephrol Hypertens 11 2002 603-607
13. Trotter J.F. Sirolimus in liver transplantation Transplant Proc 35 3 suppl 2003 S193-S200
14. Benito A.I. Furlong T. Martin P.J. et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease Transplantation 72 2001 1924-1929
15. Couriel D. Hicks K. Saliba R. et al. Sirolimus (rapamycin) for treatment of steroid-refractory chronic graft versus host disease Biol Blood Marrow Transplant 9 2003 67 (abstr.)
16. Johnston L. Shizuru J. Stockerl-Goldstein K. et al. Rapamycin for treatment of chronic graft versus host disease Biol Blood Marrow Transplant 9 2003 87-88 (abstr.)
17. Chao N.J. Snyder D.S. Jain M. et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial Biol Blood Marrow Transplant 6 2000 254-261
18. Cutler C. Antin J.H. Omission of day +11 methotrexate after matched-related allogeneic peripheral blood stem cell transplantation does not increase the risk of graft-vs.-host disease Biol Blood Marrow Transplant 8 2002 85 (abstr.)
19. Ho V.T. Weller E. Lee S.J. et al. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation Biol Blood Marrow Transplant 7 2001 223-229
20. Antin J.H. Kim H.T. Cutler C. et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation Blood 102 2003 1601-1605
21. Przepiorka D. Weisdorf D. Martin P. et al. 1994 Consensus Conference on Acute GVHD Grading Bone Marrow Transplant 15 1995 825-828
22. Monopoli M. Woo S. Valley M. Sonis S. A site-based scoring system of chemotherapy-induced oral mucositis in bone marrow transplant recipients Annual meeting of the Society for Oral Oncology 1991 (abstr.)
23. Thiede C. Florek M. Bornhauser M. et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection Bone Marrow Transplant 23 1999 1055-1060
24. Kaplan E. Meier P. Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457-481
25. Cleveland W. Robust locally weighted regression and smoothing scatterplots J Am Stat Assoc 74 1979 829-836
26. Wadleigh M. Richardson P.G. Zahrieh D. et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation Blood 102 2003 1578-1582
27. Richardson P. Murakami C. Jin C. et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome Blood 100 2003 4337-4343
28. Bensinger W.I. Martin P.J. Storer B. et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers N Engl J Med 344 2001 175-181
29. Couban S. Simpson D.R. Barnett M.J. et al. A randomized multicentre comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies Blood 100 2002 1525-1531
30. Gondo H. Harada M. Taniguchi S. et al. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease Bone Marrow Transplant 12 1993 437-441
31. Fukuda T. Hackman R. Guthrie K. et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative compared to conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation Blood 102 2003 2777-2785
32. Richardson P. Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation Acta Haematol 106 2001 57-68
33. Filicko J. Lazarus H.M. Flomenberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment Bone Marrow Transplant 31 2003 1-10
34. Epstein J.B. Phillips N. Parry J. et al. Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation Bone Marrow Transplant 30 2002 785-792
35. Papas A.S. Clark R.E. Martuscelli G. et al. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation Bone Marrow Transplant 31 2003 705-712
36. Mrsic M. Labar B. Bogdanic V. et al. Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia Bone Marrow Transplant 6 1990 137-141
37. Aschan J. Ringden O. Sundberg B. et al. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy Bone Marrow Transplant 7 1991 113-119
38. Kumar S. Chen M.G. Gastineau D.A. et al. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease Bone Marrow Transplant 27 2001 1133-1140
39. Przepiorka D. Anderlini P. Saliba R. et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation Blood 98 2001 1695-1700
40. Devine S.M. Geller R.B. Lin L.B. et al. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis Biol Blood Marrow Transplant 3 1997 25-33
41. Przepiorka D. Khouri I. Ippoliti C. et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation Bone Marrow Transplant 24 1999 763-768
42. Bacigalupo A. Zikos P. Van Lint M.-T. et al. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience Exp Hematol 26 1998 409-414
43. Blaise D. Kuentz M. Fortanier C. et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle J Clin Oncol 18 2000 537-546
44. Pavletic Z.S. Bishop M.R. Tarantolo S.R. et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies J Clin Oncol 15 1997 1608-1616
45. Schmitz N. Beksac M. Hasenclever D. et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia Blood 100 2002 761-767
46. Atkinson K. Downs K. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation Bone Marrow Transplant 16 1995 755-758
47. Kumar S. Wolf R.C. Chen M.G. et al. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease Bone Marrow Transplant 30 2002 161-165
48. Fay J.W. Wingard J.R. Antin J.H. et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation Blood 87 1996 3514-3519
49. Schwartz J. Buchbarker D. Griffin D. et al. Single-agent tacrolimus for prophylaxis of acute graft-versus-host disease after related allogeneic peripheral blood stem cell transplantation: a phase II study Biol Blood Marrow Transplant 9 2003 97 (abstr.)
50. Cutler C. Giri S. Jeyapalan S. et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis J Clin Oncol 19 2001 3685-3691
51. Ferrara J. Antin J.H. The pathophysiology of graft-vs.-host disease. In: Thomas E.D. Blume K.G. Forman S.J. (Eds.), Hematopoietic Cell Transplantation 1999 305-315 Blackwell ScienceMalden, MA
52. Hill G. Ferrara J. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation Blood 95 2000 2754-2759
53. Slavik J. Lim D. Burakoff S. Hafler D. Uncoupling p70(s6) kinase activation and proliferation: rapamycin-resistant proliferation of human CD8(+) T lymphocytes J Immunol 166 2001 3201-3209
54. Soiffer R. Gonin R. Murray C. et al. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation Blood 82 1993 2216-2223
55. Koenen H. Michielsen E. Verstappen J. Fasse E. Joosten I. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis Transplantation 75 2003 1581-1590
56. McLeod B.C. Thrombotic microangiopathies in bone marrow and organ transplant patients J Clin Apheresis 17 2002 118-123
57. Langer R.M. Van Buren C.T. Katz S.M. Kahan B.D. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination Transplantation 73 2002 756-760
58. Robson M. Cote I. Abbs I. Koffman G. Goldsmith D. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 3 2003 324-327
59. Saikali J.A. Truong L.D. Suki W.N. Sirolimus may promote thrombotic microangiopathy Am J Transplant 3 2003 229-230
60. Barone G. Gurley B. Abul-Ezz S. Gökden N. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient Am J Kidney Dis 42 2003 202-206
61. Edwards C. House A. Shahinian V. Knoll G. Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy Nephrol Dial Transplant 17 2002 1524-1526
62. Heering P. Deppe C.E. Farokhzad F. Helmchen U. Grabensee B. Hemolytic uremic syndrome after renal transplantation: immunosuppressive therapy with rapamycin Nephron 91 2002 177
63. Yango A. Morrissey P. Monaco A. Butera J. Gohh R.Y. Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange Clin Nephrol 58 2002 77-78